At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
GNLX Genelux Corporation
Pre-Market Trading 11-22 08:56:41 EST
2.46
-0.03
-1.20%
盘前2.50
+0.04+1.63%
08:49 EST
High2.56
Low2.34
Vol164.68K
Open2.56
D1 Closing2.49
Amplitude8.84%
Mkt Cap83.89M
Tradable Cap63.39M
Total Shares34.10M
T/O400.93K
T/O Rate0.64%
Tradable Shares25.77M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Genelux Corp’s Strategic Advances in Cancer Trials Position GNLX as a Promising Investment
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary, modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small-cell lung cancer. The company is also developing V2ACT Immunotherapy for the treatment of pancreatic cancer; and V-VET1, an animal health product candidate. It has a licensing agreement with ELIAS Animal Health, LLC. Genelux Corporation was incorporated in 2001 and is headquartered in Westlake Village, California.